Clinical Associate Professor Joy Ho

• Publications

Publications

2009

Brown, R, Spencer, A, Ho, P, Kennedy, N, Kabani, K, Yang, S, Sze, D, Aklilu, E, Gibson, J, Joshua, D. Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leukemia and Lymphoma. 2009; 50:1860-1864

2008

Joshua, D, Brown, R, Ho, P, Gibson, J. Regulatory T cells and Multiple Myeloma. Clinical Lymphoma & Myeloma. 2008; 8:283-286

2007

Sanders, J, Crawford, B, Gibson, J, Joy Ho, P, Iland, H, Joshua, D. Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). International journal of laboratory hematology. 2007. p. 395-397.

Osborne, R, De Abreu Lourenço, R, Dalton, A, Houltram, J, Dowton, D, Joshua, D, Lindeman, R, Ho, P. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2007; 10:451-456

2006

Sze, D, Brown, R, Yang, S, Ho, P, Gibson, J, Joshua, D. The use of thalidomide in myeloma therapy as an effective anticancer drug. Current cancer drug targets. 2006; 6:325-31

Ling, S, Joshua, D, Gibson, J, Young, G, Iland, H, Watson, G, Ho, P. Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?. American journal of hematology. 2006; 81:110-4

Trent, R, Webster, B, Bowden, D, Gilbert, A, Ho, P, Lindeman, R, Lammi, A, Rowell, J, Hinchcliffe, M, Colley, A, Wilson, M, Saleh, M, Blackwell, J, Vicki, P. Complex phenotypes in the haemoglobinopathies: recommendations on screening and DNA testing. Pathology. 2006; 38:507-519

2005

Brown, R, Ho, J. Multiple Myeloma: Methods and Protocols. New York: Humana Press, 2005.

Brown, R, Ho, J. Identification of Malignant Plasma Cells by mRNA In Situ Hybridization. Methods in Molecular Medicine. 2005; 113:175-81

Joshua, D, Brown, R, Ho, J. Multiple myeloma: challenges and opportunities. Methods in Molecular Medicine. 2005; 113:1-4

Ling, S, Campbell, L, Ho, J, Gibson, J, Joshua, D. Multiple myeloma: molecular biology, pathology and cytogenetics. In: Clinical Malignant Haematology. New York: McGraw-Hill 2005. p. ?.

2004

Gibson, J, Ho, P, Joshua, D. Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogenic. Transplantation proceedings. 2004; 36:2501-3

Gibson, J, Ho, P, Joshua, D. Low-grade lymphoma: the optimal timing. Transplantation proceedings. 2004; 36:1995-8

Brown, R, Murray, A, Pope, B, Sze, D, Gibson, J, Ho, P, Hart, D, Joshua, D. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. British journal of haematology. 2004; 125:743-8

Brown, R, Murray, A, Pope, B, Sze, D, Gibson, J, Ho, P, Joshua, D. B7+ T cells in myeloma: an acquired marker of prior chronic antigen presentation. Leukemia & lymphoma. 2004; 45:363-71

Joshua, D, Joshua, D, Gibson, J, Ho, P, brown, R. The immune system in myeloma. In: Multiple myeloma and related disorders. UK: Arnold 2004. p. 29-46.

Ho, P, Gibbins, J, Joshua, D. Treatment of multiple myeloma: current management and new approaches. American journal of cancer. 2004; 3:47-66

2003

Sze, D, Brown, R, Yuen, E, Gibson, J, Ho, J, Raitakari, M, Basten, A, Joshua, D, Fazekas de St Groth, B. Clonal cytotoxic T cells in myeloma. Leukemia & lymphoma. 2003; 44:1667-1674

Szea, D, Brown, R, Yang, S, Gibson, J, Ho, J, Fazekas de St Groth, B, Basten, A, Joshua, D. Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. Leukemia & lymphoma. 2003; 44:1557-1568

2002

Ho, P. Chromosomal and genetic abnormalities in myeloma. Clinical And Laboratory Haematology. 2002; 24:259-269

2001

Brown, R, Pope, B, Murray, A, Esdale, W, Sze, D, Gibson, J, Ho, P, Hart, D, Joshua, D. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood. 2001; 98:2992-2998

Sze, D, Giesajtis, G, Brown, R, Raitakari, M, Gibson, J, Ho, J, Baxter, A, Fazekas de St Groth, B, Basten, A, Joshua, D. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood. 2001; 98:2817-2827

Ho, P, Brown, R, Pelka, G, Basten, A, Gibson, J, Joshua, D. Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival. Blood. 2001; 97:490-5

2000

Ho, P, Thein, S. Gene regulation and deregulation: a beta globin perspective. Blood Reviews. 2000; 14:78-93